Aspira Women's Health Business Summary

Aspira Women’s Health Inc. (AWHL) is a bio-analytical company specializing in the development and commercialization of non-invasive, AI-powered diagnostic tests for gynecologic diseases. The company generates revenue primarily through its OvaSuite portfolio, which includes the FDA-cleared Ova1Plus (a combination of Ova1 and Overa) and OvaWatch, used to assess ovarian cancer risk in women with adnexal masses. Aspira’s business model has recently pivoted toward high-margin revenue growth by targeting large-scale health care systems and Integrated Delivery Networks (IDNs), moving away from a pure volume-based strategy. The company operates within the competitive molecular diagnostics and oncology screening market, facing direct competition from established players such as Myriad Genetics, Invitae, and Exact Sciences. Aspira distinguishes itself by focusing exclusively on specialized gynecologic health, utilizing proprietary algorithms to provide risk stratification that optimizes surgical referrals and patient management. As of March 2026, Aspira is led by Chief Executive Officer Michael Buhle, who joined in early 2025 with over 25 years of experience at firms like Danaher Corporation and Biovision Diagnostics. The executive team includes Chief Financial Officer Brian Hungerford, a veteran of Kiromic Biopharma with extensive SEC reporting expertise, and Chief Science Officer Dr. Todd Pappas, who oversees the company’s R&D and its ENDOinform endometriosis diagnostic pipeline. The Board of Directors is chaired by Jack Fraser, a managing partner at Seamark Capital, and includes prominent healthcare leaders such as Dr. Jeffrey Cohen and Cindy Hundorfean, both formerly of the Allegheny Health Network. Notable financial backing includes a 2025 equity purchase agreement with Triton Funds LP, which has been instrumental in supporting the company’s commercial expansion and clinical study requirements.